Detection of taxane-induced neuropathy using patient-reported outcomes
Not yet recruiting
- Conditions
- Breast cancerPeripheral neuropathy
- Registration Number
- ACTRN12618001378213
- Lead Sponsor
- Royal Adelaide Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not yet recruiting
- Sex
- Female
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie taxane-induced neuropathy in breast cancer patients?
How do patient-reported outcomes compare to standard clinical assessments for detecting taxane-induced neuropathy?
Are there specific biomarkers that predict susceptibility to taxane-induced peripheral neuropathy in breast cancer?
What are the most effective management strategies for taxane-induced neuropathy in breast cancer treatment?
How does taxane-induced neuropathy impact long-term quality of life in breast cancer survivors compared to other chemotherapies?